Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Non Operating Income (2016 - 2025)

Ultragenyx Pharmaceutical has reported Other Non Operating Income over the past 10 years, most recently at -$934000.0 for Q4 2025.

  • Quarterly Other Non Operating Income rose 79.88% to -$934000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 120.0% year-over-year, with the annual reading at $1.0 million for FY2025, 120.0% up from the prior year.
  • Other Non Operating Income was -$934000.0 for Q4 2025 at Ultragenyx Pharmaceutical, up from -$1.0 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $3.1 million in Q3 2024 and troughed at -$4.6 million in Q4 2024.
  • The 5-year median for Other Non Operating Income is -$557000.0 (2021), against an average of -$412650.0.
  • Year-over-year, Other Non Operating Income crashed 1288.06% in 2022 and then skyrocketed 666.67% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at -$410000.0 in 2021, then soared by 143.9% to $180000.0 in 2022, then skyrocketed by 666.67% to $1.4 million in 2023, then tumbled by 436.45% to -$4.6 million in 2024, then soared by 79.88% to -$934000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Non Operating Income are -$934000.0 (Q4 2025), -$1.0 million (Q3 2025), and $2.1 million (Q2 2025).